Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity in vivo Statement of Significance: Multiple recent studies have highlighted the immunosuppressive impact of MUC16/CA125 on antibodies immune effector function incl

Antibody Therapeutics (IF=4.5, Oxford University Press)
🔥🔥 Bypassing the immunosuppressive effects of CA125/MUC16 via re-engineered rituximab (NAV-006) to improve its antitumor activity in vivo
academic.oup.com/abt/article/...
#ADCC #CDC #CD20 #MUC16 #CA125 #rituximab #CD16

bsky.app/profile/did:...

better-experience.blogspot.com/2026/01/95-d...

NO #ONE #LIVES
multi-search-tag-explorer.aepiot.com/advanced-sea...
#GREENLAND 2 #MIGRATION
multi-search-tag-explorer.headlines-world.com/advanced-sea...
#CD20
headlines-world.com/advanced-sea...
headlines-world.com

ロシュ、全身性エリテマトーデス（SLE）における抗CD20抗体オビヌツズマブ（ガザイバ）の第3相で主要評価項目を達成 | STELLANEWS.LIFE ロシュの抗CD20抗体オビヌツズマブ（ガザイバ）は、第3相ALLEGORY試験で全身性エリテマトーデス（SLE）の疾患活動性を有意に低下。主要評価項目および副次評価項目を達成し、安全性は既知の範囲内で新たな懸念は確認されなかった。

Roche’s Gazyva (obinutuzumab) meets all primary and secondary endpoints in Phase 3 ALLEGORY trial for systemic lupus erythematosus (SLE).

stellanews.life/technology_c...

#Gazyva #SLE #Lupus #Obinutuzumab #CD20 #AutoimmuneDiseases #Roche #ALLEGORYtrial

CoinDesk 20 Performance Update: Index Gains 2.8% as All Constituents Move Higher The CoinDesk 20 Index climbed 2.8%, with all assets rising on the back of crypto's first regulated CFD product launch. See what drove this rally and why institutional interest is surging.

CoinDesk 20 Performance Update: Index Gains 2.8% as All Constituents Move Higher A New Era for Crypto IndicesThe CoinDesk 20 Index delivered a notable performance, rising 2.8%.... @cosmicmeta.ai #CD20

https://u2m.io/pzvm1wky

CoinDesk 20 Performance Update: Index Gains 2.8% as All Constituents Move Higher The CoinDesk 20 Index climbed 2.8%, with all assets rising on the back of crypto's first regulated CFD product launch. See what drove this rally and why institutional interest is surging.

CoinDesk 20 Performance Update: Index Gains 2.8% as All Constituents Move Higher A New Era for Crypto IndicesThe CoinDesk 20 Index delivered a notable performance, rising 2.8%.... @cosmicmeta.ai #CD20

https://u2m.io/pzvm1wky

✨ #JohnsonAndJohnson 🇺🇸 repousse la frontière des #CAR_Tcells 🧬

Lors du congrès #EHA2025 🇪🇺, J&J a dévoilé des données sur son #CAR_T 🧬 à double cible ( #CD19 + #CD20) pour le #Lymphome 🩸 à grandes cellules B R/R qui fait tourner les têtes :

J&J ties early-stage lymphoma CAR-T to 100% response rate in 10 patients Johnson & Johnson is providing a first look at

⚡️ J & J fournit les données cliniques de son programme #CAR_Tcells 🧬 à double ciblage à la fois #CD19 et #CD20 pour le #CancerDuSang 🩸

👉 #JohnsonAndJohnson établit un #CAR_T 🧬 pour le #Lymphome 🩸 avec un taux de réponse de 100 % chez 10 patients

www.fiercebiotech.com/biotech/jj-h...

The following CA House Republicans voted to cut #Medicaid (Medi-Cal in CA) to fund tax cuts for the wealthy
#CD1 - Doug LaMalfa
#CD3 - Kevin Kiley
#CD5 - Tom McClintock
#CD20 - Vince Fong
#CD22 - David Valadao
#CD23 - Jay Obernolte
#CD40 - Young Kim
#CD41 - Ken Calvert
#CD48 - Darrell Issa
#MediCal

🚀 #Cardano Leads CoinDesk 20 Gains!

The #CoinDesk 20 Index is up 0.8% as #ADA (+13.6%) and #LTC (+6.5%) drive the rally. Meanwhile, #APT (-3.5%) and #AAVE (-1.1%) lag behind. 15 of 20 assets are in the green! 🌎📈

#CryptoMarketToday #Crypto #CD20 #Altcoins #Altcoin

#bloodcancer #lymphoma #leukemia #myeloma #gerontology #cancer #AI #healthcare #ehealth #digitalhealth #CD20 #immunology #ecology #ecotoxicology #sustainability #prevention #datascience

Resumen del mercado

#Bitcoin, cotiza por encima de los $102.970 1.59%

$ENA 18% 🚀
$HNT 7.35% 🚀
$STX 6.90% 🚀

📌Market Cap: $3.65 T 1.06%
📌Dominio de #BTC 55.82%
📌Dominio de ETH 12.83%
📌Índice de Altcoin Season 65%
📌Índice de miedo y codicia 77
📌Índice #CMC100 $225.44 1.12%
📌 Índice #CD20 3.830 0.40%

Study from Iran: 10 MS patients safely switched from anti-CD20 to lower-intensity treatments. After 18 months, no disease progression seen. Suggests de-escalation could be viable for stable patients to reduce long-term risks.

pubmed.ncbi.nlm.nih.gov/39619757/

#MS #CD20

Representative CD20 staining of spleen and mandibular lymph node sections from animals treated with vehicle or CD20-NKCE-IL2v (0.5 mg/kg). Scale bars: 3 mm

This week in #ScienceImmunology: Olivier Demaria, Eric Vivier, & al. use tetraspecific #NKCell engager (comprising an anti- #NKp46 Ab fragment + #IgG1 #Fc fragment + #IL2 variant + anti- #CD20 Ab) to target #BCell -specific #NonHodgkin #lymphoma (B-NHL) in mouse & NHP models!

bit.ly/SI_adp3720